Donal Mulligan - GILEAD SCIENCES CFO, Executive Vice President
| GIS Stock | EUR 62.77 0.00 0.00% |
President
Mr. Donal Leo Mulligan serves as Chief Financial Officer, Executive Vice President of General Mills, Inc. Mr. Mulligan joined General Mills in 2001 from The Pillsbury Company. He served as Vice President, Financial Operations for our International division until 2004, when he was named Vice President, Financial Operations for Operations and Technology. Mr. Mulligan was appointed Treasurer in 2006 and Senior Vice President, Financial Operations in 2007. He was elected to his present position in 2007. From 1987 to 1998, he held several international positions at PepsiCo, Inc. and YUM Brands, Inc. Mr. Mulligan is a director of Tennant Company. since 2007.
| Age | 57 |
| Tenure | 17 years |
GILEAD SCIENCES Leadership Team
Elected by the shareholders, the GILEAD SCIENCES's board of directors comprises two types of representatives: GILEAD SCIENCES inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GILEAD. The board's role is to monitor GILEAD SCIENCES's management team and ensure that shareholders' interests are well served. GILEAD SCIENCES's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GILEAD SCIENCES's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jerald Young, Vice President Controller | ||
| Olivier Faujour, Vice President and Presidentident - Dairy Strategic Brand Unit | ||
| Jacqueline WilliamsRoll, Senior Vice President - Human Resources | ||
| Donal Mulligan, CFO, Executive Vice President | ||
| Jon Nudi, Group President - North America Retail | ||
| Bethany Quam, Group President - Europe & Australia | ||
| Kofi Bruce, Principal Accounting Officer, Vice President Controller | ||
| Alicia Davis, Independent Director | ||
| Jeff Siemon, Director | ||
| Jeffrey Harmening, Executive Vice President COO, U. S. Retail | ||
| Eric Sprunk, Independent Director | ||
| John Church, Executive Vice President - Supply Chain | ||
| Robert Ryan, Independent Director | ||
| Dorothy Terrell, Independent Director | ||
| Kerry Clark, Independent Director | ||
| Roger Ferguson, Independent Director | ||
| Kimberly Nelson, Senior Vice President - External Relations and Presidentident - General Mills Foundation | ||
| Kendall Powell, Chairman of the Board, CEO | ||
| Henrietta Fore, Director | ||
| Kristen Winker, Senior Vice President - Investor Relations | ||
| Maria Henry, Independent Director | ||
| Christopher OLeary, Executive Vice President COO - International | ||
| Sean Walker, Group President - Asia & Latin America | ||
| Elizabeth Lempres, Director | ||
| Shawn OGrady, Senior Vice President and Presidentident - Sales and Channel Development | ||
| Jorge Uribe, Independent Director | ||
| Michael Rose, Independent Director | ||
| Peter Erickson, Executive Vice President - Innovation, Technology and Quality | ||
| Maria Sastre, Independent Director | ||
| Richard Allendorf, General Counsel | ||
| Jonathon Nudi, Senior Vice President and Presidentident - U.S. Retail | ||
| Paul Danos, Independent Director | ||
| Heidi Miller, Independent Director | ||
| Stephen Odland, Independent Director | ||
| David Cordani, Independent Director | ||
| Diane Neal, Director | ||
| Christina Law, Senior Vice President Group President - Asia & Latin America | ||
| Bradbury Anderson, Independent Director |
GILEAD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GILEAD SCIENCES a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 125.35 B | |||
| Price To Book | 5.21 X | |||
| Price To Sales | 4.07 X | |||
| Revenue | 27.28 B | |||
| EBITDA | 6.75 B | |||
| Net Income | 4.59 B | |||
| Total Debt | 25.18 B | |||
| Cash Flow From Operations | 9.07 B | |||
| Price To Earnings To Growth | 0.70 X | |||
| Number Of Employees | 38 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GILEAD SCIENCES in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GILEAD SCIENCES's short interest history, or implied volatility extrapolated from GILEAD SCIENCES options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GILEAD SCIENCES. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade GILEAD Stock refer to our How to Trade GILEAD Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for GILEAD Stock analysis
When running GILEAD SCIENCES's price analysis, check to measure GILEAD SCIENCES's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GILEAD SCIENCES is operating at the current time. Most of GILEAD SCIENCES's value examination focuses on studying past and present price action to predict the probability of GILEAD SCIENCES's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GILEAD SCIENCES's price. Additionally, you may evaluate how the addition of GILEAD SCIENCES to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |